Next Article in Journal
Solution NMR Structure of the SH3 Domain of Human Caskin1 Validates the Lack of a Typical Peptide Binding Groove and Supports a Role in Lipid Mediator Binding
Next Article in Special Issue
Computer Navigation and 3D Printing in the Surgical Management of Bone Sarcoma
Previous Article in Journal
Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
Previous Article in Special Issue
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
Open AccessFeature PaperReview

Future Directions in the Treatment of Osteosarcoma

Sarcoma Unit, Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK
Pediatric Hematology Oncology and Bone Marrow Transplantation, Cleveland Clinic R3 Main Campus, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Orthopedic Oncology Services, Department of Surgical Oncology, Tata Memorial Hospital, HBNI, Mumbai 400012, India
The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
Author to whom correspondence should be addressed.
Cells 2021, 10(1), 172;
Received: 12 December 2020 / Revised: 11 January 2021 / Accepted: 13 January 2021 / Published: 15 January 2021
(This article belongs to the Special Issue Research Advances and Therapy of Human Osteosarcoma)
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy. View Full-Text
Keywords: osteosarcoma; chemotherapy; MAP; immunotherapy; genomic heterogeneity; adolescent and young adult; patient outcomes osteosarcoma; chemotherapy; MAP; immunotherapy; genomic heterogeneity; adolescent and young adult; patient outcomes
MDPI and ACS Style

Smrke, A.; Anderson, P.M.; Gulia, A.; Gennatas, S.; Huang, P.H.; Jones, R.L. Future Directions in the Treatment of Osteosarcoma. Cells 2021, 10, 172.

AMA Style

Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021; 10(1):172.

Chicago/Turabian Style

Smrke, Alannah; Anderson, Peter M.; Gulia, Ashish; Gennatas, Spyridon; Huang, Paul H.; Jones, Robin L. 2021. "Future Directions in the Treatment of Osteosarcoma" Cells 10, no. 1: 172.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop